Single-dose radiosurgical treatment for hepatic metastases - therapeutic outcome of 138 treated lesions from a single institution

Habermehl, Daniel; Herfarth, Klaus K; Bermejo, Justo Lorenzo; Hof, Holger; Rieken, Stefan; Kuhn, Sabine; Welzel, Thomas; Debus, Jürgen; Combs, Stephanie E

doi:10.1186/1748-717X-8-175

Table 3 Literature overview

From: Single-dose radiosurgical treatment for hepatic metastases - therapeutic outcome of 138 treated lesions from a single institution

Author	Year	Primary tumour	Number of patients	Number of fractions	Overall dose	Local control	Details
Herfarth et al. [14]	2001	Mets and PLC	56	1	14 – 26 Gy	67% after 18 months
Wulf et al. [15]	2001	Mets and PLC	56	3	27 pts. 3 x 10 Gy 1 pt. 4 x 7 Gy	61% after 2 years PLT: 100% after median f/u 15 mo.
					19 pts. 3 x 12-12.5 Gy
					1 pt. 1 x 26 Gy
Schefter et al. [16]	2005	Mets	18	3	9 Pts.: 36 Gy	Not reported	Phase-I study
Schefter et al. [16]	2005	Mets	18	3	9 Pts.: 60 Gy	Not reported	Phase-I study
Hoyer et al. [17]	2006	Mets	44	3	45	Not reported	Phase-II study, Liver-specific data not reported
Kavanagh et al. [18]	2006	Mets	36	3	60 Gy	93% after 18 months	Phase-I/II study
Mendez-Romero et al. [19]	2006	Mets and PLC	45	3	37.5 Gy	82% after 2 years	Phase-I/II study
Mendez-Romero et al. [19]	2006	Mets and PLC	45	3	(also 5 x 5 Gy or 3 x 10 Gy)	82% after 2 years	Phase-I/II study
Katz et al. [27]	2007	Mets	174	7 – 20	30 – 55 Gy	57% after 20 months	Lesion diameter ranged from 0.6 – 12.2 cm
Katz et al. [27]	2007	Mets	174	7 – 20	median 48 Gy	57% after 20 months	Lesion diameter ranged from 0.6 – 12.2 cm
Rusthoven et al. [11]	2009	Mets	63	3	36 – 60 Gy	95%, 92% after 1 and 2 years	Phase-I/II study
Lee et al. [12]	2009	Mets	68	6	27.7 – 60 Gy	71% after 1 year	Phase-I study
Lee et al. [12]	2009	Mets	68	6	median 41.8 Gy	71% after 1 year	Phase-I study
Van der Pool et al. [20]	2010	Mets	31	3	12.5 Gy (n = 29)	74% after 2 years	Grade III toxicities were hepatic
Van der Pool et al. [20]	2010	Mets	31	3	15 Gy (n = 2)	74% after 2 years	Grade III toxicities were hepatic
Goodman et al. [21]	2010	Mets and PLC	40	1	18 – 30 Gy	77% after 1 year	Phase-I study
Rule et al. [28]	2011	Mets	37	3 or 5	30 – 60 Gy	56%, 89%,100% for 30, 50 and 60-Gy after 2 years	Phase-I study
Rule et al. [28]	2011	Mets	37	3 or 5	(30 Gy/3 fx, 50 and 60 Gy in 5 fx)	56%, 89%,100% for 30, 50 and 60-Gy after 2 years	Phase-I study
Chang et al. [29]	2011	Mets	65	1-6	22–60 Gy, median 42 Gy	67%, 55% after 1 and 2 years
Vautravers-Dewas et al. [41]	2011	Mets	42	3-4	40 Gy/4 fx, 45 Gy/3 fx	86% after 2 years
Lanciano et al. [40]	2012	Mets and PLC	30	3 or 5	79.2–180 Gy10	75%, 57% with BED10 >100 Gy after 1 and 2 years
Lanciano et al. [40]	2012	Mets and PLC	30	3 or 5	(66–150 Gy BED2)	75%, 57% with BED10 >100 Gy after 1 and 2 years
This study	2013	Mets	138	1	10-30 Gy, median 24 Gy	87%, 69% and 59% after 6, 12 and 18 months

HCC without cirrhosis, and HCC < 4 cm with cirrhosis were mostly treated with 3 ×12.5 Gy. Patients with HCC ≥ 4 cm and cirrhosis received 5 × 5 Gy or 3 × 10 Gy. Gy Gray, CRC colorectal carcinoma, mets metastases, Pts. Patients, Pt. patient, DLT Dose-limiting toxicity, PLC Primary Liver cancer, fx fractions, LC Local Control.

Back to article page

ISSN: 1748-717X

Contact us

General enquiries: journalsubmissions@springernature.com

Radiation Oncology

Contact us